BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease

Core Insights - BioRestorative Therapies, Inc. announced positive results from its Phase 2 clinical trial for hypoxic-cultured mesenchymal stem cells in treating chronic lumbar disc disease, with over 50% of patients reporting significant improvements in pain and function [1][2] - The study showed no adverse events related to dose-limiting toxicities, reinforcing the safety profile of the treatment [1][3] - The company is preparing for a potential Phase 3 clinical trial following alignment with the U.S. FDA on key trial elements [3][4] Clinical Trial Results - 50% or more of treated patients reported improvements greater than 50% in key pain and functional outcome measures [1] - On the Visual Analog Scale (VAS), 53.57% of patients reported over 50% improvement at 26 weeks, increasing to 75% at 52 weeks and remaining at 75% at 104 weeks [6] - For the Oswestry Disability Index (ODI), 53.57% of patients achieved over 50% improvement at 26 weeks, rising to 74.63% at 52 weeks, with 50% maintaining that improvement at 104 weeks [7] - Improvements were also noted in the Roland-Morris Disability Questionnaire (RMDQ) and Functional Rating Index (FRI), with significant percentages of patients showing sustained improvements over time [8][9] Future Development Plans - The company is transitioning from clinical evaluation to registrational planning, preparing for the next stage of clinical development, including protocol planning for Phase 3 [4] - The company aims to continue generating clinical data to support the advancement and potential commercialization of BRTX-100 [4] Company Overview - BioRestorative focuses on developing therapeutic products using adult stem cells, with core programs targeting disc/spine disease and metabolic disorders [10][11] - The lead candidate, BRTX-100, is designed for non-surgical treatment of painful lumbosacral disc disorders, utilizing proprietary technology for stem cell collection and injection [11] - The company also operates a BioCosmeceutical platform, developing products aimed at skin health and longevity [11]